Treatment complications in children diagnosed with neuroblastoma during a screening program

被引:16
作者
Barrette, SP
Bernstein, ML
Leclerc, JM
Champagne, MA
Samson, Y
Brossard, J
Woods, WG
机构
[1] Hop St Justine, Montreal, PQ H3T 1C5, Canada
[2] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[3] Ctr Hosp Univ Laval, Ste Foy, PQ, Canada
[4] Ctr Univ Sante Estrie, Sherbrooke, PQ, Canada
[5] Emory Univ, AFLAC Canc Ctr, Atlanta, GA 30322 USA
[6] Childrens Healthcare Atlanta, Atlanta, GA USA
关键词
D O I
10.1200/JCO.2005.04.4602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The Quebec Neuroblastoma Screening Program was put in place to investigate the possibility of decreasing mortality from high-risk neuroblastoma through early screening. We assess treatment complications in the patients diagnosed during this screening program, Patients and Methods A total of 476,603 patients born during the screening period were eligible. Parents of 425,838 children (89%) agreed to participate in the 3-week screening, and 73% agreed to participate in the 6-month screening. Forty-five patients had neuroblastoma. We reviewed the medical and research charts for all patients diagnosed by screening. Follow-up was available from 8 to 13 years after screening. Results Forty-five patients were diagnosed by screening. All patients were treated according to the Pediatric Oncology Group recommendations of the time. All patients had surgery, and 29 patients received chemotherapy. No patient died from neuroblastoma. Eleven patients suffered complications from treatment. Two patients had life-threatening complications. Conclusion In view of the lack of impact of screening programs on neuroblastoma mortality, evidence that many of the tumors detected through screening can be observed without treatment and the serious complications that may arise from therapy, we do not support neuroblastoma screening programs for children.
引用
收藏
页码:1542 / 1545
页数:4
相关论文
共 17 条
[1]   THIN-LAYER CHROMATOGRAPHY OF URINARY HOMOVANILLIC-ACID AND VANILLYLMANDELIC ACID FOR LARGE-SCALE NEURO-BLASTOMA MASS-SCREENING [J].
AURAYBLAIS, C ;
GIGUERE, R ;
LEMIEUX, B .
MEDICAL AND PEDIATRIC ONCOLOGY, 1989, 17 (05) :364-367
[2]  
Brodeur GM, 2001, MED PEDIATR ONCOL, V36, P157, DOI 10.1002/1096-911X(20010101)36:1<157::AID-MPO1038>3.0.CO
[3]  
2-F
[4]   Biology and treatment of neuroblastoma [J].
Castleberry, RP .
PEDIATRIC CLINICS OF NORTH AMERICA, 1997, 44 (04) :919-&
[5]   Wait and see strategy in localized neuroblastoma in infants: An option not only for cases detected by mass screening [J].
Fritsch, P ;
Kerbl, R ;
Lackner, H ;
Urban, C .
PEDIATRIC BLOOD & CANCER, 2004, 43 (06) :679-682
[6]   Surgical treatment of neuroblastomas in infants under 12 months of age [J].
Ikeda, H ;
Suzuki, N ;
Takahashi, A ;
Kuroiwa, M ;
Nagashima, K ;
Tsuchida, Y ;
Matsuyama, S .
JOURNAL OF PEDIATRIC SURGERY, 1998, 33 (08) :1246-1250
[7]   Maturation of mass-screened localized adrenal neuroblastoma [J].
Iwanaka, T ;
Yamamoto, K ;
Ogawa, Y ;
Arai, M ;
Ito, M ;
Kishimoto, H ;
Hanada, R ;
Imaizumi, S .
JOURNAL OF PEDIATRIC SURGERY, 2001, 36 (11) :1633-1636
[8]  
Kerbl R, 1997, MED PEDIATR ONCOL, V29, P1, DOI 10.1002/(SICI)1096-911X(199707)29:1<1::AID-MPO1>3.0.CO
[9]  
2-J
[10]   Neuroblastoma mass screening in late infancy: Insights into the biology of neuroblastic tumors [J].
Kerbl, R ;
Urban, CE ;
Ambros, IM ;
Dornbusch, HJ ;
Schwinger, W ;
Lackner, H ;
Ladenstein, R ;
Strenger, V ;
Gadner, H ;
Ambros, PF .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4228-4234